Janice Suzann Drew Sells 20,000 Shares of Evommune (NYSE:EVMN) Stock

Evommune, Inc. (NYSE:EVMN) insider Janice Suzann Drew sold 20,000 shares of Evommune stock in a transaction on Monday, June 22nd. The stock was sold at an average price of $22.63, for a total value of $452,600.00. Following the sale, the insider owned 67,794 shares of the company’s stock, valued at approximately $1,534,178.22. This trade represents a 22.78% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is accessible through the SEC website.

Evommune Trading Up 1.9%

NYSE EVMN opened at $24.00 on Friday. The company’s 50-day moving average price is $23.02 and its 200-day moving average price is $22.29. The stock has a market cap of $864.43 million and a PE ratio of -2.53. Evommune, Inc. has a 12 month low of $13.89 and a 12 month high of $33.20.

Evommune (NYSE:EVMN) last posted its quarterly earnings results on Thursday, May 7th. The company reported ($0.64) EPS for the quarter, topping the consensus estimate of ($0.83) by $0.19. As a group, sell-side analysts forecast that Evommune, Inc. will post -2.85 earnings per share for the current year.

Analysts Set New Price Targets

Several research firms have recently weighed in on EVMN. Stifel Nicolaus assumed coverage on shares of Evommune in a research note on Friday, May 1st. They set a “buy” rating and a $54.00 price target for the company. Wall Street Zen downgraded Evommune from a “hold” rating to a “sell” rating in a report on Saturday, June 13th. Royal Bank Of Canada reaffirmed an “outperform” rating and set a $48.00 target price on shares of Evommune in a research report on Friday, April 10th. Morgan Stanley upped their target price on Evommune from $54.00 to $55.00 and gave the stock an “overweight” rating in a report on Monday, May 11th. Finally, Clear Str raised Evommune to a “strong-buy” rating in a research report on Tuesday, March 17th. Three investment analysts have rated the stock with a Strong Buy rating, nine have assigned a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the company. According to data from MarketBeat.com, the company has an average rating of “Buy” and an average price target of $49.25.

Institutional Investors Weigh In On Evommune

Several large investors have recently modified their holdings of the business. Strs Ohio purchased a new stake in shares of Evommune in the 1st quarter worth approximately $41,000. China Universal Asset Management Co. Ltd. purchased a new position in Evommune during the fourth quarter valued at approximately $34,000. The Manufacturers Life Insurance Company raised its stake in Evommune by 25.3% in the first quarter. The Manufacturers Life Insurance Company now owns 12,812 shares of the company’s stock worth $295,000 after buying an additional 2,587 shares in the last quarter. XTX Topco Ltd bought a new position in Evommune in the fourth quarter worth approximately $321,000. Finally, Oxford Asset Management LLP purchased a new stake in Evommune during the fourth quarter worth $335,000.

Evommune Company Profile

Evommune is a clinical-stage biotechnology company developing innovative therapies that target key drivers of chronic inflammatory diseases, with initial clinical development programs focusing on chronic spontaneous urticaria (“CSU”), atopic dermatitis (“AD”) and ulcerative colitis (“UC”). Chronic inflammation is a significant healthcare problem in the world, substantially impacting patients’ quality of life and leading to life-threatening conditions. These conditions, if not prevented, ultimately lead to fatal diseases, such as cardiovascular diseases, diabetes and cancer, which contribute to three out of every five deaths worldwide and result in an estimated $90 billion of annual cost to the healthcare system in the United States.